



Corrigendum: New Tools for Epilepsy Therapy

Chiara Falcicchia¹, Michele Simonato^{1,2} and Gianluca Verlengia^{1,2*}

¹ Department of Medical Sciences, Section of Pharmacology, and Neuroscience Center, University of Ferrara and National Institute of Neuroscience, Ferrara, Italy, ² School of Medicine, University Vita-Salute San Raffaele, Milan, Italy

Keywords: epilepsy, cell therapy, delivery devices, gene therapy, herpes-based vector

A corrigendum on

New Tools for Epilepsy Therapy

by Falcicchia, C., Simonato, M., and Verlengia, G. (2018). *Front. Cell. Neurosci.* 12:147. doi: 10.3389/fncel.2018.00147

In the original article, we made the incorrect statement that non-viral vectors do not work *in vivo*, as below:

“Although the use of non-viral vectors could be attractive as they are generally safe, cheap and relative easy to produce, these approaches do not work *in vivo*”

This mistake was due to the fact that we meant to refer to epilepsy. Non-viral vectors have provided promising results for other applications, even if less for central nervous system disorders and in no case for epilepsy.

A correction has been made to section “Gene Therapy Approaches”, Paragraph 3:

In the past few years, the use of non-viral vectors has made a big step up for both *in vitro* and *in vivo* applications (Hardee et al., 2017). If compared to their viral counterpart, these tools are deemed to be generally safer, cheaper and relatively easier to produce. However, their employment for *in vivo* CNS targeting is still hindered by inadequate efficiency of transduction and transient expression of the transgene. At least so far, there is no evidence of efficacy for epilepsy treatment in preclinical or clinical studies by delivery of nucleic acids through non-viral systems.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

OPEN ACCESS

Approved by:

Frontiers In Cellular Neuroscience
Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Gianluca Verlengia
verlengia.gianluca@hsr.it

Received: 26 June 2018

Accepted: 27 June 2018

Published: 11 July 2018

Citation:

Falcicchia C, Simonato M and
Verlengia G (2018) Corrigendum: New
Tools for Epilepsy Therapy.
Front. Cell. Neurosci. 12:212.
doi: 10.3389/fncel.2018.00212

REFERENCES

Hardee, C. L., Arévalo-Soliz, L. M., Hornstein, B. D., and Zechiedrich, L. (2017). Advances in non-viral DNA vectors for gene therapy. *Genes* 8:65. doi: 10.3390/genes8020065

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Falcicchia, Simonato and Verlengia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.